13929-35-6 Usage
Uses
Different sources of media describe the Uses of 13929-35-6 differently. You can refer to the following data:
1. A Rifamycin (R508200) derivative as antibacterial agent.
2. Rifamycin B (Rifaximin EP Impurity B) is a Rifamycin (R508200) derivative as antibacterial agent.
Purification Methods
Rifamycin B forms yellow needles from *C6H6. Its solubilities are: H2O (0,027%), MeOH (2.62%) and EtOH (0.44%). It has UV max at 223, 304 and 245nm (A 1cm 555, 275 and 220). [Oppolzer & Prelog Helv Chim Acta 56 2287 1973, Oppolzer et al. Experientia 20 336 1964, X-ray: Brufani et al. Experientia 20 339 1964.]
Check Digit Verification of cas no
The CAS Registry Mumber 13929-35-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,9,2 and 9 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 13929-35:
(7*1)+(6*3)+(5*9)+(4*2)+(3*9)+(2*3)+(1*5)=116
116 % 10 = 6
So 13929-35-6 is a valid CAS Registry Number.
InChI:InChI=1/C39H49NO14/c1-17-11-10-12-18(2)38(49)40-24-15-26(51-16-27(42)43)28-29(34(24)47)33(46)22(6)36-30(28)37(48)39(8,54-36)52-14-13-25(50-9)19(3)35(53-23(7)41)21(5)32(45)20(4)31(17)44/h10-15,17,19-21,25,31-32,35,44-47H,16H2,1-9H3,(H,40,49)(H,42,43)/b11-10+,14-13+,18-12+/t17-,19-,20+,21-,25-,31-,32+,35+,39-/m0/s1
13929-35-6Relevant articles and documents
Deciphering the late steps of rifamycin biosynthesis
Qi, Feifei,Lei, Chao,Li, Fengwei,Zhang, Xingwang,Wang, Jin,Zhang, Wei,Fan, Zhen,Li, Weichao,Tang, Gong-Li,Xiao, Youli,Zhao, Guoping,Li, Shengying
, (2018/06/26)
Rifamycin-derived drugs, including rifampin, rifabutin, rifapentine, and rifaximin, have long been used as first-line therapies for the treatment of tuberculosis and other deadly infections. However, the late steps leading to the biosynthesis of the industrially important rifamycin SV and B remain largely unknown. Here, we characterize a network of reactions underlying the biosynthesis of rifamycin SV, S, L, O, and B. The two-subunit transketolase Rif15 and the cytochrome P450 enzyme Rif16 are found to mediate, respectively, a unique C-O bond formation in rifamycin L and an atypical P450 ester-to-ether transformation from rifamycin L to B. Both reactions showcase interesting chemistries for these two widespread and well-studied enzyme families.
